Martyn D. Greenacre

This profile gathers the share dealings of Martyn D. Greenacre across 5 companies, led by Cephalon Inc, Curis Inc and Beijing Med Pharm Corp. In total, 78 filings cover trades dated from 17 February 2006 to 23 January 2019.

Market trades split into 15 purchases (€33k) and 32 sales (€3.9M). The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 13 share grants and 16 option exercises. 2019 to date brings no purchases and 1 sale.

In size, the median ticket on the buying side is €1,381. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -41.3%. This is a record of the past, not a forecast.

The latest filing, published on 25 January 2019, reports an open-market sale of €17k in Curis Inc. The last insider purchase was made public on 11 May 2012, 5,278 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.